Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer

Table 4

Multivariate Cox regression analysis of PFS of 33 advanced colorectal cancer patients.

Characteristics	HR	95% CI
Number of previous chemotherapy lines	5.941	1.765–19.991	0.004
Excision of primary lesion	0.215	0.54–0.853	0.029
ECOG	—	—	0.364
Primary tumor location	—	—	0.753
Bevacizumab	—	—	0.087
Lung metastases	—	—	0.111

ECOG, Eastern Cooperative Oncology Group performance status.